Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the election of Sue Washer, President and Chief Executive Officer, to the Biotechnology Innovation Organization (BIO)'s Board of Directors. Read More »

Label Variation to Include Overall Survival Data From Phase 3 ENDEAVOR Trial Read More »

Amgen and Humana Inc. will collaborate on finding opportunities to improve health outcomes by analyzing the real-world health care experiences of Humana's 13 million members. Read More »

Amgen and Allergan submitted a Biologics License Application for ABP 980, a biosimilar candidate to Herceptin, to the U.S. Food and Drug Administration. Read More »

California-based Amgen recently obtained U.S. Food and Drug Administration (FDA) acceptance of its Biologics License Application (BLA) for Aimovig (erenumab), a product developed specifically to help victims of frequent migraine headaches. Read More »

Amgen and UCB recently announced that their Evenity study, which analyzed the drug as a treatment for postmenopausal women with osteoporosis, met both primary endpoints and the secondary endpoint. Read More »

Amgen of Thousand Oaks, California and Array BioPharma of Boulder, Colorado recently created a cooperative contract to develop innovative drugs aimed at combating autoimmune disorders after Array’s breakthrough discovery of certain target and lead inhibitors. Read More »

HedgePath Pharmaceuticals Inc. (HPPI) recently announced that the U.S. Food and Drug Administration (FDA) granted the company’s Type-C Guidance Meeting Request for further guidance on HPPI’s Phase 2(b) clinical trial analyzing SUBA-Itraconazole (SUBA-Cap) oral capsule usage in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS), also known as Gorlin Syndrome. Read More »

Amgen's Xgeva Phase 3 study, the largest international multiple myeloma trial ever conducted, met its primary endpoint by demonstrating that the drug is non-inferior to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma. Read More »

Amgen's Phase 2 study evaluating Imlygic combined with Yervoy as a treatment for patients with unresectable Stage IIIB-IV met its​ primary endpoint. Read More »

Via tax-free allotment to company shareholders, Rennova Health Inc. intends to transition its Advanced Molecular Services Group to a publicly traded entity by late September pending appropriate paperwork with the SEC and other conditions. Read More »

Amgen recently announced that its Mimpara drug has been given a positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency. Read More »

A prescription chemotherapy drug manufactured by Florida-based Breckenridge Pharmaceutical Inc. has earned Food and Drug Administration approval, moving a step closer to combating a rare type of blood and bone marrow cancer. Read More »

Amgen recently presented 19 scientific abstracts at the 59th Annual Scientific Meeting of the American Headache Society, which took place in Boston. Read More »

Amgen and Allergan's data supporting their Biologics License Application for ABP 215, a biosimilar candidate to Avastin (bevacizumab), will be reviewed by the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration by July 13. Read More »

Amgen's Fourier trial for Repatha met its primary composite endpoint and the key secondary composite endpoint. Read More »

TapImmune Inc. has completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, which is a multi-epitope T-cell vaccine developed by the company that targets the folate receptor alpha. Read More »

Amgen announced May 18 a Biologics License Application which they submitted to the U.S. Food and Drug Administration for a migraine prevention medication. Read More »

Amgen announced May 2 that they had signed an outcome-based refund contract with Harvard Pilgrim for Amgen's Repatha. Read More »

Amgen recently shared positive results for its Fourier Trial, which is evaluating whether Repatha reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease. Read More »